New issues in bacterial infections in solid organ transplant recipients

Infections in Medicine

Volumn 21, Issue 5, 2004, Pages 234-244

  Issa, Nicolas C ^a   Patel, Robin ^a  

^a Mayo Clinic   (United States)

Author keywords

Burkholderia cepacia; Drug resistance; Mycobacteria; Nocardia species; Solid organ; Transplantation

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAMASE; CEPHALOSPORIN; CHLORHEXIDINE; COTRIMOXAZOLE; LINEZOLID; METICILLIN; NORFLOXACIN; PSEUDOMONIC ACID; RAMOPLANIN; SULFONAMIDE; TRIMETHOPRIM; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BURKHOLDERIA CEPACIA; CYTOMEGALOVIRUS; DRUG USE; ENTEROBACTER; ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; IMMUNE DEFICIENCY; INFECTION CONTROL; KIDNEY TRANSPLANTATION; KLEBSIELLA PNEUMONIAE; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MENINGITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; MYCOBACTERIOSIS; MYCOBACTERIUM; NEISSERIA MENINGITIDIS; NOCARDIA; NOCARDIOSIS; ORGAN DONOR; ORGAN TRANSPLANTATION; PNEUMOCYSTIS; POSTOPERATIVE INFECTION; PROPHYLAXIS; RECIPIENT; SURGICAL TECHNIQUE; TREATMENT CONTRAINDICATION;

EID: 2942522704     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Singh N, Paterson DL, Chang FY, et al. Methicillin-resistant Staphylococcus aureus: the other emerging resistant gram-positive coccus among liver transplant recipients. Clin Infect Dis. 2000;30:322-327.
2. Rebuck JA, Olsen KM, Fey PD, et al. Characterization of an outbreak due to extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a pediatric intensive care unit transplant population. Clin Infect Dis. 2000;31:1368-1372.
3. Singh N, Gayowski T, Rihs JD, et al. Evolving trends in multiple-antibiotic-resistant bacteria in liver transplant recipients: a longitudinal study of antimicrobial susceptibility patterns [published correction appears in Liver Transpl. 2001;7:471]. Liver Transpl. 2001;7:22-26.
4. Satoi S, Bramhall SR, Solomon M, et al. The use of liver grafts from donors with bacterial meningitis. Transplantation. 2001;72:1108-1113.
5. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control. 1999;27:520-532.
6. Baden LR, Thiemke W, Skolnik A, et al. Prolonged colonization with vancomycin-resistant Enterococcus faecium in long-term care patients and the significance of "clearance." Clin Infect Dis. 2001;33:1654-1660.
7. Montecalvo MA, de Lencastre H, Carraher M, et al. Natural history of colonization with vancomycin-resistant Enterococcus faecium. Infect Control Hosp Epidemiol. 1995;16:680-685.
8. D'Agata EM, Green WK, Schulman G, et al. Vancomycin-resistant enterococci among chronic hemodialysis patients: a prospective study of acquisition. Clin Infect Dis. 2001;32:23-29.
9. Donskey CJ, Hanrahan JA, Hutton RA, Rice LB. Effect of parenteral antibiotic administration on the establishment of colonization with vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract. J Infect Dis. 2000; 181:1830-1833.
10. Donskey CJ, Chowdhry TK, Hecker MT, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med. 2000;343:1925-1932.
11. MacIntyre CR, Empson M, Boardman C, et al. Risk factors for colonization with vancomycin-resistant enterococci in a Melbourne hospital. Infect Control Hosp Epidemiol. 2001;22:624-629.
12. Quale J, Landman D, Saurina G, et al. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis. 1996;23:1020-1025.
13. Bradley SJ, Wilson AL, Allen MC, et al. The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage. J Antimicrob Chemother. 1999;43:261-266.
14. Ostrowsky BE, Venkataraman L, D'Agata EM, et al. Vancomycin-resistant enterococci in intensive care units: high frequency of stool carriage during a non-outbreak period. Arch Intern Med. 1999;159:1467-1472.
15. Pfundstein J, Roghmann MC, Schwalbe RS, et al. A randomized trial of surgical antimicrobial prophylaxis with and without vancomycin in organ transplant patients. Clin Transpl. 1999;13: 245-252.
16. Patel R, Allen SL, Manahan JM, et al. Natural history of vancomycin-resistant enterococcal colonization in liver and kidney transplant recipients. Liver Transpl. 2001;7:27-31.
17. Herrero IA, Issa NC, Patel R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med. 2002;346:867-869.
18. Patel R. Clinical impact of vancomycin-resistant enterococci. J Antimicrob Chemother. 2003; 51(suppl. S3):iii13-iii21.
19. Gonzales RD, Schreckenberger PC, Graham MB, et al. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet. 2001;357:1179.
20. Newell KA, Millis JM, Arnow PM, et al. Incidence and outcome of infection by vancomycin-resistant Enterococcus following orthotopic liver transplantation. Transplantation. 1998;65:439-442.
21. Orloff SL, Busch AM, Olyaei AJ, et al. Vancomycin-resistant Enterococcus in liver transplant patients. Am J Surg. 1999;177:418-422.
22. Wong MT, Kauffman CA, Standiford HC, et al. Effective suppression of vancomycin-resistant Enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin. Clin Infect Dis. 2001;33:1476-1482.
23. Baden LR, Critchley IA, Sahm DF, et al. Molecular characterization of vancomycin-resistant enterococci repopulating the gastrointestinal tract following treatment with a novel glycolipodepsipeptide, ramoplanin. J Clin Microbiol. 2002;40:1160-1163.
24. Bert F, Galdbart JO, Zarrouk V, et al. Association between nasal carriage of Staphylococcus aureus and infection in liver transplant recipients. Clin Infect Dis. 2000;31:1295-1299.
25. Chang FY, Singh N, Gayowski T, et al. Staphylococcus aureus nasal colonization and association with infections in liver transplant recipients. Transplantation. 1998;65:1169-1172.
26. Paterson DL, Rihs JD, Squier C, et al. Lack of efficacy of mupirocin in the prevention of infections with Staphylococcus aureus in liver transplant recipients and candidates. Transplantation. 2003;75:194-198.
27. Babini GS, Livermore DM. Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998. J Antimicrob Chemother. 2000; 45:183-189.
28. Lucet JC, Decre D, Fichelle A, et al. Control of a prolonged outbreak of extended-spectrum beta-lactamase-producing Enterobacteriaceae in a university hospital. Clin Infect Dis. 1999; 29:1411-1418.
29. Meyer KS, Urban C, Eagan JA, et al. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med. 1993;119:353-358.
30. Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA. 1998;280:1233-1237.
31. Schiappa DA, Hayden MK, Matushek MG, et al. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. J Infect Dis. 1996;174:529-536.
32. Paterson DL, Singh N, Rihs JD, et al. Control of an outbreak of infection due to extended-spectrum. beta-lactamase-producing Escherichia coli in a liver transplantation unit. Clin Infect Dis. 2001;33:126-128.
33. Singh N. Antimicrobial strategies for the prevention of infections in liver transplant recipients. Infect Med. 2002;19:428-435.
34. Aris RM, Routh JC, LiPuma JJ, et al. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type. Am J Respir Crit Care Med. 2001;164:2102-2106.
35. Chaparro C, Maurer J, Gutierrez C, et al. Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med. 2001;163:43-48.
36. Coenye T, Vandamme P, LiPuma JJ, et al. Updated version of the Burkholderia cepacia complex experimental strain panel. J Clin Microbiol. 2003;41:2797-2798.
37. Vandamme P, Holmes B, Coenye T, et al. Burkholderia cenocepacia sp. nov. - a new twist to an old story. Res Microbiol. 2003;154:91-96.
38. Vandamme P, Henry D, Coenye T, et al. Burkholderia anthina sp. nov. and Burkholderia pyrrocinia, two additional Burkholderia cepacia complex bacteria, may confound results of new molecular diagnostic tools. FEMS Immunol Med Microbiol. 2002;33:143-149.
39. Vermis K, Coenye T, Mahenthiralingam E, et al. Evaluation of species-specific recA-based PCR tests for genomovar level identification within the Burkholderia cepacia complex. J Med Microbiol. 2002;51:937-940.
40. Husain S, Singh N. Burkholderia cepacia infection and lung transplantation. Semin Respir Infect. 2002;17:284-290.
41. Mahenthiralingam E, Baldwin A, Vandamme P. Burkholderia cepacia complex infection in patients with cystic fibrosis. J Med Microbiol. 2002; 51:533-538.
42. De Soyza A, McDowell A, Archer L, et al. Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis. Lancet. 2001;358:1780-1781.
43. Cantarovich M, Tchervenkov J, Loertscher R. Transplantation of kidneys from a donor with Neisseria meningitidis infection. Am J Nephrol. 1993;13:171-172.
44. Freeman RB, Giatras I, Falagas ME, et al. Outcome of transplantation of organs procured from bacteremic donors. Transplantation. 1999; 68:1107-1111.
45. Little DM, Farrell JG, Cunningham PM, Hickey DP. Donor sepsis is not a contraindication to cadaveric organ donation. QJM. 1997;90:641-642.
46. Lopez-Navidad A, Domingo P, Caballero F, et al. Successful transplantation of organs retrieved from donors with bacterial meningitis. Transplantation. 1997;64:365-368.
47. Paig i JM, Lopez-Navidad A, Lloveras J, et al. Organ donors with adequately treated bacterial meningitis may be suitable for successful transplantation. Transplant Proc. 2000;32:75-77.
48. Doig RL, Boyd PJ, Eykyn S. Staphylococcus aureus transmitted in transplanted kidneys. Lancet. 1975;2:243-245.
49. First MR, Linnemann CC, Munda R, et al. Transmitted streptococcal infection and hyper-acute rejection. Possible cross-reaction of streptococcal antigens and antibodies with mammalian tissues. Transplantation. 1977;24:400-404.
50. Nelson PW, Delmonico FL, Tolkoff-Rubin NE, et al. Unsuspected donor pseudomonas infection causing arterial disruption after renal transplantation. Transplantation. 1984;37:313-314.
51. Rubin RH, Fishman JA. A consideration of potential donors with active infection - is this a way to expand the donor pool? Transpl Int. 1998;11:333-335.
52. Skogberg K, Syrjanen J, Jahkola M, et al. Clinical presentation and outcome of listeriosis in patients with and without immunosuppressive therapy. Clin Infect Dis. 1992;14:815-821.
53. Patel R, Roberts GD, Keating MR, Paya CV. Infections due to nontuberculous mycobacteria in kidney, heart, and liver transplant recipients. Clin Infect Dis. 1994;19:263-273.
54. Novick RJ, Moreno-Cabral CE, Stinson EB, et al. Nontuberculous mycobacterial infections in heart transplant recipients: a seventeen-year experience. J Heart Transplant. 1990;9:357-363.
55. Christiansen DC, Roberts GD, Patel R. Mycobacterium celatum, an emerging pathogen and cause of false-positive Amplified Mycobacterium tuberculosis Direct Test. Diagn Microbiol Infect Dis. In press.
56. Wallace RJ Jr, Brown-Elliott BA, Ward SC, et al. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother. 2001;45:764-767.
57. Moylett EH, Pacheco SE, Brown-Elliott BA, et al. Clinical experience with linezolid for the treatment of Nocardia infection. Clin Infect Dis. 2003;36:313-318.